Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 6/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.38 |
| ▸ | STK17B | O94768 | 2/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449322 | 0.87 | MAPK1 (0.47) | ULK1STK17ASTK17BMAPK1SYK | |
| SCHEMBL3450906 | 0.86 | ULK1 (0.36) | ULK1STK17ATNIKNUDT1FEN1 | |
| SCHEMBL3449320 | 0.85 | MAPK1 (0.42) | ULK1STK17ASTK17BMAPK1CTSC | |
| SCHEMBL3450762 | 0.82 | STK17A (0.41) | ULK1STK17ASTK17BMAPK1SYK | |
| SCHEMBL3450566 | 0.82 | ULK1 (0.38) | ULK1STK17ASTK17BMAPK1SYK | |
| SCHEMBL3375503 | 0.82 | SYK (0.40) | ULK1MAPK1SYK | |
| SCHEMBL3372082 | 0.82 | XDH (0.40) | ULK1SYK | |
| SCHEMBL3374672 | 0.81 | SYK (0.48) | SYK | |
| SCHEMBL3450069 | 0.81 | SYK (0.42) | ULK1STK17ASTK17BMAPK1SYK | |
| SCHEMBL3452335 | 0.81 | IDH1 (0.47) | ULK1STK17ASTK17BMAPK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ULK1 2054/4885STK17A 1984/4885STK17B 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.